Metastatic Uveal Melanoma Clinical Trial
Official title:
Phase I/II Study of BET and MEK Inhibition in Advanced Uveal Melanoma
This phase I/II trial tests the safety, side effects, and best dose of PLX2853 in combination with trametinib in treating patients with uveal (eye) melanoma that has spread to other places in the body (metastatic) or nearby tissues or lymph nodes (locally advanced), or that cannot be removed by surgery (unresectable). PLX2853 works by targeting and inhibiting certain activities within cells that promote tumor growth. By inhibiting these activities, PLX2853 may help to stabilize or reduce the growth of tumor cells. Trametinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving PLX2853 in combination with trametinib may help to shrink and stabilize tumor cells in patients with advanced uveal melanoma.
CO-PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose(s) (MTD(s)) and recommended phase II dose. (Phase I) II. To evaluate whether combination BRD4 inhibitor PLX2853 (PLX2853) and trametinib demonstrate clinical activity in advanced uveal melanoma (UM), as determined by a best response rate of 25% compared to a historical rate of 10%. (Phase II) SECONDARY OBJECTIVES: I. To evaluate the overall response rate (ORR) associated with combination PLX2853 and trametinib. II. To evaluate the progression-free survival (PFS) associated with combination PLX2853 and trametinib. III. To evaluate the overall survival (OS) associated with combination PLX2853 and trametinib. IV. To characterize the adverse event profile associated with combination PLX2853 and trametinib. PHARMACOKINETICS SECONDARY OBJECTIVE: I. To evaluate the pharmacokinetic profile of combination PLX2853 and trametinib. OUTLINE: This is a phase I dose-escalation study of PLX2853 and trametinib followed by a phase II study. Patients receive PLX2853 orally (PO) in combination with trametinib PO throughout the study. Patients also undergo computed tomography (CT) or magnetic resonance imaging (MRI) with contrast and collection of blood at screening and on study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03068624 -
Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
|
Phase 1 | |
| Recruiting |
NCT04728633 -
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
|
Phase 2 | |
| Recruiting |
NCT05987332 -
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
|
Phase 2/Phase 3 | |
| Completed |
NCT01551459 -
A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma
|
Phase 2 | |
| Active, not recruiting |
NCT00986661 -
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
|
Phase 1 | |
| Completed |
NCT01585194 -
Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
|
Phase 2 | |
| Withdrawn |
NCT01328106 -
Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma
|
Phase 2 | |
| Recruiting |
NCT05075993 -
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT04552223 -
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
|
Phase 2 | |
| Recruiting |
NCT05607095 -
Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma
|
Phase 1 | |
| Active, not recruiting |
NCT01587352 -
Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
|
Phase 2 | |
| Active, not recruiting |
NCT03025256 -
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
|
Phase 1 | |
| Active, not recruiting |
NCT03472586 -
Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
|
Phase 2 | |
| Terminated |
NCT04879017 -
FHD-286 in Subjects With Metastatic Uveal Melanoma
|
Phase 1 | |
| Terminated |
NCT01814046 -
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
|
Phase 2 | |
| Recruiting |
NCT03947385 -
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03865212 -
Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma
|
Phase 1 | |
| Active, not recruiting |
NCT05022901 -
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
|
Phase 3 | |
| Recruiting |
NCT05282901 -
Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)
|
Phase 2 | |
| Recruiting |
NCT05415072 -
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
|
Phase 1/Phase 2 |